Benitec Biopharma Inc. (BNTC)Healthcare | Biotechnology | Hayward, United States | NasdaqCM
12.99 USD
-0.43
(-3.204%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 12.99 |
Hot Take ↕ | July 11, 2026, 6:42 a.m. EDT
Benitec Biopharma presents a classic 'value trap' scenario where aggressive analyst upgrades and index additions clash with a brutal historical reality. While the company recently posted a +34.67% gain and was added to the Russell 2000 Value benchmark, these positives occur against a backdrop of a -96% cumulative decline over the last nine years. The business is fundamentally distressed, burning cash at a rapid rate with negative returns on equity and assets, and relies entirely on a proposed public offering to survive. The massive gap between the current price ($13.42) and the analyst mean target ($25.80) is not a margin of safety but a reflection of high-risk speculation on a drug candidate's success, not a valuation of a profitable enterprise. With zero dividends, a beta of 0.25 indicating low correlation to broader moves (likely due to lack of liquidity), and no institutional support beyond the latest news cycle, the security lacks the fundamental durability required for a long-term hold. The short-term outlook remains neutral-to-slightly-bearish because the statistical models see no immediate trend reversal, and the options market shows no conviction in a near-term bounce. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.064733 |
| AutoARIMA | 0.064920 |
| AutoETS | 0.064921 |
| AutoTheta | 0.083501 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 1.96 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.542 |
| Excess Kurtosis | -0.74 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Last Dividend Date | 2018-05-31 |
| Debt to Equity Ratio | 0.478 |
| Market Cap | 446,262,816 |
| Forward P/E | -1.38 |
| Beta | 0.25 |
| Website | https://benitec.com |
As of July 11, 2026, 6:42 a.m. EDT: Options activity is extremely thin with negligible volume and open interest across both calls and puts. Implied volatility is elevated relative to the low trading volume, suggesting speculative pricing rather than genuine positioning. There is no discernible directional bias from speculators; the lack of significant flow at key strikes indicates the market is effectively on the sidelines regarding near-term catalysts.
| Date | Dividend | Yield % |
|---|---|---|
| 2018-06-01 | 0.765 | 0.118203 |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.012830138 |
| Address1 | 3,940 Trust Way |
| All Time High | 5,916.0 |
| All Time Low | 1.86 |
| Ask | 16.69 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 195,880 |
| Average Daily Volume3 Month | 117,457 |
| Average Volume | 117,457 |
| Average Volume10Days | 195,880 |
| Beta | 0.252 |
| Bid | 9.67 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 5.337 |
| City | Hayward |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 12.99 |
| Current Ratio | 56.816 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 13.48 |
| Day Low | 12.8454 |
| Debt To Equity | 0.478 |
| Dividend Date | 1,574,035,200 |
| Earnings Timestamp | 1,778,761,800 |
| Earnings Timestamp End | 1,778,761,800 |
| Earnings Timestamp Start | 1,778,761,800 |
| Ebitda | -46,541,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -5.638 |
| Enterprise Value | 262,377,792 |
| Eps Forward | -9.42 |
| Eps Trailing Twelve Months | -0.93 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 11.8938 |
| Fifty Day Average Change | 1.0962 |
| Fifty Day Average Change Percent | 0.092165664 |
| Fifty Two Week Change Percent | 1.2830138 |
| Fifty Two Week High | 16.76 |
| Fifty Two Week High Change | -3.7700005 |
| Fifty Two Week High Change Percent | -0.22494036 |
| Fifty Two Week Low | 9.85 |
| Fifty Two Week Low Change | 3.1399994 |
| Fifty Two Week Low Change Percent | 0.31878164 |
| Fifty Two Week Range | 9.85 - 16.76 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,403,616,600,000 |
| Float Shares | 17,925,061 |
| Forward Eps | -9.42 |
| Forward P E | -1.3789809 |
| Free Cashflow | -7,130,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 19 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02549 |
| Held Percent Institutions | 0.98309 |
| Implied Shares Outstanding | 34,354,334 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Dividend Date | 1,527,811,200 |
| Last Dividend Value | 0.765 |
| Last Fiscal Year End | 1,751,241,600 |
| Last Split Date | 1,690,329,600 |
| Last Split Factor | 1:17 |
| Long Business Summary | Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California. |
| Long Name | Benitec Biopharma Inc. |
| Market | us_market |
| Market Cap | 446,262,816 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_4492928 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -41,542,000 |
| Next Fiscal Year End | 1,782,777,600 |
| Non Diluted Market Cap | 461,035,162 |
| Number Of Analyst Opinions | 5 |
| Open | 13.4 |
| Operating Cashflow | -19,792,000 |
| Operating Margins | 0.0 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 510 780 0819 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 12.99 |
| Post Market Time | 1,783,981,119 |
| Previous Close | 13.42 |
| Price Hint | 2 |
| Price To Book | 2.4339516 |
| Profit Margins | 0.0 |
| Quick Ratio | 56.434 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.16667 |
| Region | US |
| Regular Market Change | -0.43 |
| Regular Market Change Percent | -3.20417 |
| Regular Market Day High | 13.48 |
| Regular Market Day Low | 12.8454 |
| Regular Market Day Range | 12.8454 - 13.48 |
| Regular Market Open | 13.4 |
| Regular Market Previous Close | 13.42 |
| Regular Market Price | 12.99 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 85,451 |
| Return On Assets | -0.19933 |
| Return On Equity | -0.29578 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 34,354,334 |
| Shares Percent Shares Out | 0.064899996 |
| Shares Short | 2,228,682 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 2,332,180 |
| Short Name | Benitec Biopharma Inc. |
| Short Percent Of Float | 0.1148 |
| Short Ratio | 15.07 |
| Source Interval | 15 |
| State | CA |
| Symbol | BNTC |
| Target High Price | 32.0 |
| Target Low Price | 18.0 |
| Target Mean Price | 25.8 |
| Target Median Price | 25.0 |
| Total Cash | 184,760,992 |
| Total Cash Per Share | 5.378 |
| Total Debt | 876,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.93 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 12.512275 |
| Two Hundred Day Average Change | 0.47772503 |
| Two Hundred Day Average Change Percent | 0.03818051 |
| Type Disp | Equity |
| Volume | 85,451 |
| Website | https://benitec.com |
| Zip | 94,545 |